{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:31Z","timestamp":1793916031719,"version":"4.8.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"DOI":"10.1038\/s41586-026-11088-0","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:04:23Z","timestamp":1790780663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GPCR antagonism via rewiring of receptor trafficking and degradation"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-8946","authenticated-orcid":false,"given":"Kaitlin","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-9270","authenticated-orcid":false,"given":"Lawrence","family":"Shue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimasa","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-4444","authenticated-orcid":false,"given":"James","family":"Osei-Owusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingjingyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-2199","authenticated-orcid":false,"given":"Aoxing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-7891","authenticated-orcid":false,"given":"Apoorva","family":"Baluapuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-334X","authenticated-orcid":false,"given":"Karen","family":"Adelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-6775","authenticated-orcid":false,"given":"Meredith A.","family":"Skiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-5629","authenticated-orcid":false,"given":"Bianxiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1540-6244","authenticated-orcid":false,"given":"Jun R.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1222","authenticated-orcid":false,"given":"Andrew C.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-2856","authenticated-orcid":false,"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"11088_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schi\u00f6th, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829\u2013842 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11088_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/antib12020030","volume":"12","author":"S G\u00f3mez-Melero","year":"2023","unstructured":"G\u00f3mez-Melero, S. & Caballero-Villarraso, J. CCR6 as a potential target for therapeutic antibodies for the treatment of inflammatory diseases. Antibodies 12, 30 (2023).","journal-title":"Antibodies"},{"key":"11088_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1128\/JVI.79.1.536-546.2005","volume":"79","author":"SJ Paulsen","year":"2005","unstructured":"Paulsen, S. J., Rosenkilde, M. M., Eugen-Olsen, J. & Kledal, T. N. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 79, 536\u2013546 (2005).","journal-title":"J. Virol."},{"key":"11088_CR4","doi-asserted-by":"publisher","first-page":"e142677","DOI":"10.1172\/JCI142677","volume":"131","author":"HE Burston","year":"2021","unstructured":"Burston, H. E. et al. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. J. Clin. Invest. 131, e142677 (2021).","journal-title":"J. Clin. Invest."},{"key":"11088_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"JS Lorente","year":"2025","unstructured":"Lorente, J. S. et al. GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 24, 458\u2013479 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11088_CR6","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1021\/acs.biochem.7b00747","volume":"56","author":"A Manglik","year":"2017","unstructured":"Manglik, A. & Kruse, A. C. Structural basis for G protein-coupled receptor activation. Biochemistry 56, 5628\u20135634 (2017).","journal-title":"Biochemistry"},{"key":"11088_CR7","doi-asserted-by":"publisher","first-page":"103138","DOI":"10.1016\/j.copbio.2024.103138","volume":"87","author":"ML Downey","year":"2024","unstructured":"Downey, M. L. & Peralta-Yahya, P. Technologies for the discovery of G protein-coupled receptor-targeting biologics. Curr. Opin. Biotechnol. 87, 103138 (2024).","journal-title":"Curr. Opin. Biotechnol."},{"key":"11088_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tips.2017.11.009","volume":"39","author":"K Eichel","year":"2018","unstructured":"Eichel, K. & von Zastrow, M. Subcellular organization of GPCR signaling. Trends Pharmacol. Sci. 39, 200\u2013208 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"11088_CR9","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"11088_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","volume":"638","author":"D Zhang","year":"2024","unstructured":"Zhang, D. et al. Transferrin receptor targeting chimeras for membrane protein degradation. Nature 638, 787\u2013795 https:\/\/doi.org\/10.1038\/s41586-024-07947-3 (2024).","journal-title":"Nature"},{"key":"11088_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41586-024-07948-2","volume":"638","author":"B Huang","year":"2025","unstructured":"Huang, B. et al. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature 638, 796\u2013804 (2025).","journal-title":"Nature"},{"key":"11088_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291\u2013297 (2020).","journal-title":"Nature"},{"key":"11088_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jacs.0c10008","volume":"143","author":"AD Cotton","year":"2021","unstructured":"Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143, 593\u2013598 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"11088_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","volume":"41","author":"K Pance","year":"2023","unstructured":"Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273\u2013281 (2023).","journal-title":"Nat. Biotechnol."},{"key":"11088_CR15","doi-asserted-by":"publisher","first-page":"39912","DOI":"10.1021\/jacs.5c15047","volume":"147","author":"F Zhao","year":"2025","unstructured":"Zhao, F. et al. Hijacking extracellular targeted protein degrader-drug conjugates for enhanced drug delivery. J. Am. Chem. Soc. 147, 39912\u201339925 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"11088_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","volume":"610","author":"H Marei","year":"2022","unstructured":"Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature 610, 182\u2013189 (2022).","journal-title":"Nature"},{"key":"11088_CR17","doi-asserted-by":"publisher","first-page":"103050","DOI":"10.1016\/j.copbio.2023.103050","volume":"85","author":"K Rhee","year":"2024","unstructured":"Rhee, K. & Zhou, X. Two in one: the emerging concept of bifunctional antibodies. Curr. Opin. Biotechnol. 85, 103050 (2024).","journal-title":"Curr. Opin. Biotechnol."},{"key":"11088_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41573-023-00833-z","volume":"23","author":"JA Wells","year":"2024","unstructured":"Wells, J. A. & Kumru, K. Extracellular targeted protein degradation: an emerging modality for drug discovery. Nat. Rev. Drug Discov. 23, 126\u2013140 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11088_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf6249","volume":"382","author":"G Ahn","year":"2023","unstructured":"Ahn, G. et al. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382, eadf6249 (2023).","journal-title":"Science"},{"key":"11088_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1083\/jcb.97.2.329","volume":"97","author":"C Harding","year":"1983","unstructured":"Harding, C., Heuser, J. & Stahl, P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329\u2013339 (1983).","journal-title":"J. Cell Biol."},{"key":"11088_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.phrs.2017.05.008","volume":"125","author":"T Kawai","year":"2017","unstructured":"Kawai, T. et al. AT1 receptor signaling pathways in the cardiovascular system. Pharmacol. Res. 125, 4\u201313 (2017).","journal-title":"Pharmacol. Res."},{"key":"11088_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1194","volume":"8","author":"T-Y Chen","year":"2020","unstructured":"Chen, T.-Y. et al. The relaxin family peptide receptor 1 (RXFP1): an emerging player in human health and disease. Mol. Genet. Genomic Med. 8, e1194 (2020).","journal-title":"Mol. Genet. Genomic Med."},{"key":"11088_CR23","doi-asserted-by":"publisher","first-page":"102846","DOI":"10.1016\/j.autrev.2021.102846","volume":"20","author":"HT Meitei","year":"2021","unstructured":"Meitei, H. T., Jadhav, N. & Lal, G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmun. Rev. 20, 102846 (2021).","journal-title":"Autoimmun. Rev."},{"key":"11088_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.peptides.2018.04.011","volume":"111","author":"K Kuba","year":"2019","unstructured":"Kuba, K., Sato, T., Imai, Y. & Yamaguchi, T. Apelin and Elabela\/Toddler; double ligands for APJ\/Apelin receptor in heart development, physiology, and pathology. Peptides 111, 62\u201370 (2019).","journal-title":"Peptides"},{"key":"11088_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D., Young, A., Teng, M. W. L. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17, 709\u2013724 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"11088_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/2040622313518227","volume":"5","author":"K Alagha","year":"2014","unstructured":"Alagha, K. et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chronic Dis. 5, 85\u201398 (2014).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"11088_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.cell.2017.03.022","volume":"169","author":"BT Lobingier","year":"2017","unstructured":"Lobingier, B. T. et al. An approach to spatiotemporally resolve protein interaction networks in living cells. Cell 169, 350\u2013360.e12 (2017).","journal-title":"Cell"},{"key":"11088_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Design and production of bispecific antibodies. Antibodies 8, 43 (2019).","journal-title":"Antibodies"},{"key":"11088_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/19420862.2018.1564510","volume":"11","author":"M Neiveyans","year":"2019","unstructured":"Neiveyans, M. et al. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs 11, 593\u2013605 (2019).","journal-title":"MAbs"},{"key":"11088_CR30","doi-asserted-by":"crossref","unstructured":"David, M., Cohen, R. et al. Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system. J. Control. Release 388, 114344 (2025).","DOI":"10.1016\/j.jconrel.2025.114344"},{"key":"11088_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41589-024-01620-6","volume":"20","author":"MA Skiba","year":"2024","unstructured":"Skiba, M. A. et al. Antibodies expand the scope of angiotensin receptor pharmacology. Nat. Chem. Biol. 20, 1577\u20131585 https:\/\/doi.org\/10.1038\/s41589-024-01620-6 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"11088_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax7379","volume":"6","author":"Y Ma","year":"2020","unstructured":"Ma, Y. et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Sci. Adv. 6, eaax7379 (2020).","journal-title":"Sci. Adv."},{"key":"11088_CR33","unstructured":"Liu, S., Zhao, X. & Changyun, H. U. Anti-adenosine receptor (a2aR) antibodies. World Patent WO2022072601A1 (2023)."},{"key":"11088_CR34","doi-asserted-by":"publisher","unstructured":"Paul, S. et al. Machine learning enables efficient and effective affinity maturation of nanobodies. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.01.11.698911 (2026).","DOI":"10.64898\/2026.01.11.698911"},{"key":"11088_CR35","unstructured":"Zhao, X. & Changyun, H. U. Anti-adenosine receptor (a2ar) antibodies and the use thereof. World Patent WO2023192489A2 (2023)."},{"key":"11088_CR36","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1038\/emboj.2010.168","volume":"29","author":"ML Halls","year":"2010","unstructured":"Halls, M. L. & Cooper, D. M. F. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, \u03b2-arrestin 2, PDE4D3 complex. EMBO J. 29, 2772\u20132787 (2010).","journal-title":"EMBO J."},{"key":"11088_CR37","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1021\/acsptsci.3c00053","volume":"6","author":"MA Hossain","year":"2023","unstructured":"Hossain, M. A. et al. Development of novel high-affinity antagonists for the relaxin family peptide receptor 1. ACS Pharmacol. Transl. Sci. 6, 842\u2013853 (2023).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"11088_CR38","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1038\/onc.2017.11","volume":"36","author":"D Basuli","year":"2017","unstructured":"Basuli, D. et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene 36, 4089\u20134099 (2017).","journal-title":"Oncogene"},{"key":"11088_CR39","doi-asserted-by":"publisher","first-page":"168649","DOI":"10.1016\/j.jmb.2024.168649","volume":"436","author":"JW Beugelink","year":"2024","unstructured":"Beugelink, J. W., Sweep, E., Janssen, B. J. C., Snijder, J. & Pronker, M. F. Structural basis for recognition of the FLAG-tag by anti-FLAG M2. J. Mol. Biol. 436, 168649 (2024).","journal-title":"J. Mol. Biol."},{"key":"11088_CR40","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1128\/JVI.01608-10","volume":"85","author":"J Zuo","year":"2011","unstructured":"Zuo, J. et al. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. J. Virol. 85, 1604\u20131614 (2011).","journal-title":"J. Virol."},{"key":"11088_CR41","doi-asserted-by":"publisher","first-page":"e94821","DOI":"10.1172\/jci.insight.94821","volume":"2","author":"R Robert","year":"2017","unstructured":"Robert, R. et al. Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice. JCI Insight 2, e94821 (2017).","journal-title":"JCI Insight"},{"key":"11088_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1124\/jpet.122.001452","volume":"386","author":"W Li","year":"2023","unstructured":"Li, W. et al. A novel C-C chemoattractant cytokine (chemokine) receptor 6 (CCR6) antagonist (PF-07054894) distinguishes between homologous chemokine receptors, increases basal circulating CCR6+ T cells, and ameliorates interleukin-23-induced skin inflammation. J. Pharmacol. Exp. Ther. 386, 80\u201392 (2023).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"11088_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nri2972","volume":"11","author":"TJ Schall","year":"2011","unstructured":"Schall, T. J. & Proudfoot, A. E. I. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Rev. Immunol. 11, 355\u2013363 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"11088_CR44","unstructured":"Lissilaa, R. et al. Antibodies that bind to ccr6 and their uses. World Patent WO2016059253A1 (2016)."},{"key":"11088_CR45","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1210\/en.2008-1385","volume":"150","author":"A Kern","year":"2009","unstructured":"Kern, A. & Bryant-Greenwood, G. D. Characterization of relaxin receptor (RXFP1) desensitization and internalization in primary human decidual cells and RXFP1-transfected HEK293 cells. Endocrinology 150, 2419\u20132428 (2009).","journal-title":"Endocrinology"},{"key":"11088_CR46","doi-asserted-by":"publisher","first-page":"C1058","DOI":"10.1152\/ajpcell.00581.2008","volume":"296","author":"GE Callander","year":"2009","unstructured":"Callander, G. E., Thomas, W. G. & Bathgate, R. A. D. Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of \u03b2-arrestin recruitment. Am. J. Physiol. Cell Physiol. 296, C1058\u2013C1066 (2009).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"11088_CR47","doi-asserted-by":"publisher","first-page":"13169","DOI":"10.1074\/jbc.RA120.014330","volume":"295","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Angiotensin II type 1 receptor variants alter endosomal receptor-\u03b2-arrestin complex stability and MAPK activation. J. Biol. Chem. 295, 13169\u201313180 (2020).","journal-title":"J. Biol. Chem."},{"key":"11088_CR48","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1210\/mend.12.10.0179","volume":"12","author":"WG Thomas","year":"1998","unstructured":"Thomas, W. G., Motel, T. J., Kule, C. E., Karoor, V. & Baker, K. M. Phosphorylation of the angiotensin II (AT1A) receptor carboxyl terminus: a role in receptor endocytosis. Mol. Endocrinol. 12, 1513\u20131524 (1998).","journal-title":"Mol. Endocrinol."},{"key":"11088_CR49","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T. & Giovannucci, E. L. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 314, 1818\u20131830 (2015).","journal-title":"JAMA"},{"key":"11088_CR50","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","volume":"60","author":"M Bullo","year":"2012","unstructured":"Bullo, M., Tschumi, S., Bucher, B. S., Bianchetti, M. G. & Simonetti, G. D. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60, 444\u2013450 (2012).","journal-title":"Hypertension"},{"key":"11088_CR51","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta, P. K. & Griendling, K. K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82\u2013C97 (2007).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"11088_CR52","doi-asserted-by":"publisher","first-page":"17260","DOI":"10.1073\/pnas.2002352117","volume":"117","author":"FS Alfonso","year":"2020","unstructured":"Alfonso, F. S. et al. Label-free optical detection of bioelectric potentials using electrochromic thin films. Proc. Natl Acad. Sci. USA 117, 17260\u201317268 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11088_CR53","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/bcp.12724","volume":"80","author":"S Jurcevic","year":"2015","unstructured":"Jurcevic, S. et al. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br. J. Clin. Pharmacol. 80, 1324\u20131336 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"11088_CR54","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L van der Fits","year":"2009","unstructured":"van der Fits, L. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J. Immunol. 182, 5836\u20135845 (2009).","journal-title":"J. Immunol."},{"key":"11088_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/exd.13067","volume":"26","author":"MP Sch\u00f6n","year":"2017","unstructured":"Sch\u00f6n, M. P., Broekaert, S. M. C. & Erpenbeck, L. Sexy again: the renaissance of neutrophils in psoriasis. Exp. Dermatol. 26, 305\u2013311 (2017).","journal-title":"Exp. Dermatol."},{"key":"11088_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13581","volume":"7","author":"TP Singh","year":"2016","unstructured":"Singh, T. P. et al. Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation. Nat. Commun. 7, 13581 (2016).","journal-title":"Nat. Commun."},{"key":"11088_CR57","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.chembiol.2021.02.024","volume":"28","author":"G Ahn","year":"2021","unstructured":"Ahn, G., Banik, S. M. & Bertozzi, C. R. Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem. Biol. 28, 1072\u20131080 (2021).","journal-title":"Cell Chem. Biol."},{"key":"11088_CR58","doi-asserted-by":"publisher","unstructured":"Kougentakis, C. et al. Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.01.12.632472 (2025).","DOI":"10.1101\/2025.01.12.632472"},{"key":"11088_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52975-2","volume":"15","author":"ZR Crook","year":"2024","unstructured":"Crook, Z. R. et al. CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect. Nat. Commun. 15, 8731 (2024).","journal-title":"Nat. Commun."},{"key":"11088_CR60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nsmb.3014","volume":"22","author":"WK Kroeze","year":"2015","unstructured":"Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362\u2013369 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"11088_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00219-21","volume":"95","author":"JM Edwards","year":"2021","unstructured":"Edwards, J. M. et al. Enhancement of antibody-dependent cellular cytotoxicity and phagocytosis in anti-HIV-1 human-bovine chimeric broadly neutralizing antibodies. J. Virol. 95, e0021921 (2021).","journal-title":"J. Virol."},{"key":"11088_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2018.01.006","volume":"95","author":"NM Stapleton","year":"2018","unstructured":"Stapleton, N. M. et al. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport. Mol. Immunol. 95, 1\u20139 (2018).","journal-title":"Mol. Immunol."},{"key":"11088_CR63","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1021\/acs.molpharmaceut.6b00153","volume":"13","author":"KJ Hamblett","year":"2016","unstructured":"Hamblett, K. J. et al. Altering antibody-drug conjugate binding to the neonatal Fc receptor impacts efficacy and tolerability. Mol. Pharm. 13, 2387\u20132396 (2016).","journal-title":"Mol. Pharm."},{"key":"11088_CR64","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1074\/jbc.M116.748525","volume":"292","author":"FW Jacobsen","year":"2017","unstructured":"Jacobsen, F. W. et al. Engineering an IgG scaffold lacking effector function with optimized developability. J. Biol. Chem. 292, 1865\u20131875 (2017).","journal-title":"J. Biol. Chem."},{"key":"11088_CR65","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41589-023-01321-6","volume":"19","author":"SC Erlandson","year":"2023","unstructured":"Erlandson, S. C. et al. The relaxin receptor RXFP1 signals through a mechanism of autoinhibition. Nat. Chem. Biol. 19, 1013\u20131021 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"11088_CR66","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1021\/acs.molpharmaceut.4c00368","volume":"21","author":"SC Erlandson","year":"2024","unstructured":"Erlandson, S. C. et al. Engineering and characterization of a long-half-life relaxin receptor RXFP1 agonist. Mol. Pharm. 21, 4441\u20134449 (2024).","journal-title":"Mol. Pharm."},{"key":"11088_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61708-y","volume":"16","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y. et al. Ultrasensitive label-free optical recording of bioelectric potentials using dioxythiophene-based electrochromic polymers. Nat. Commun. 16, 6776 (2025).","journal-title":"Nat. Commun."},{"key":"11088_CR68","doi-asserted-by":"publisher","unstructured":"Rhee. K. & Shue, L. GTAC. Zenodo\u00a0https:\/\/doi.org\/10.5281\/zenodo.21964502 (2026).","DOI":"10.5281\/zenodo.21964502"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11088-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T14:01:45Z","timestamp":1792936905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11088-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":68,"alternative-id":["11088"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-11088-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.Z. is a co-founder, equity holder and advisor of atida bio; a scientific founder, equity holder and advisor of VincenTx; and has received research funding from Merck unrelated to this work. A.C.K. is a co-founder and consultant for Tectonic Therapeutic and Seismic Therapeutics, and for the Institute for Protein Innovation, a nonprofit research institute. K.A. is a consultant to Odyssey Therapeutics, serves on the Scientific Advisory Board of CAMP4 Therapeutics and has received research funding from Novartis unrelated to this work. K.R., L.S., D.Z., J.O-O., A.C., A.C.K. and X.Z. have filed patent applications covering the GTAC technologies (PCT\/US2025\/020274, PCT\/US2025\/020271, PCT\/US2025\/060865, PCT\/US26\/36667 and two unpublished provisional applications).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}